{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051573","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.852613+00:00","generated_at":"2026-06-03T00:44:00.600901+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT","bullets":["Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.","Launched BBOT oncology subsidiary with $200M private financing led by Cormorant and Omega.","Secured up to $1.5B via Bayer licensing (up to $310M milestones), royalty financing, and equity.","Acoramidis NDA PDUFA date Nov 29, 2024; EMA MAA accepted, expected approval 2025.","Ended Q1 with $519.8M cash; cash position strengthened significantly."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051573","json":"https://secwatch.observer/filing/0000950170-24-051573.json","markdown":"https://secwatch.observer/filing/0000950170-24-051573.md","text":"https://secwatch.observer/filing/0000950170-24-051573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/0000950170-24-051573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/bbio-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:44:00.600901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec368573e5e819bcf84451c09845a07cada43c14","claim":"BridgeBio Pharma, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"BridgeBio Pharma, Inc. reported recent business updates and its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/0000950170-24-051573-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}